Lantheus Holdings Inc

NASDAQ:LNTH   3:59:17 PM EDT
25.17
+0.55 (+2.23%)
Products

Lantheus Receives U.S. FDA Approval Of Pylarify® (Piflufolastat F 18) Injection, The First And Only Commercially Available Psma Pet Imaging Agent For Prostate Cancer

Published: 05/27/2021 11:38 GMT
Lantheus Holdings Inc (LNTH) - Lantheus Receives U.S. FDA Approval of Pylarify® (piflufolastat F 18) Injection, the First and Only Commercially Available Psma Pet Imaging Agent for Prostate Cancer.
Lantheus Holdings Inc - Pylarify Will Be Available Immediately to Imaging Centers in Parts of Mid-atlantic and Southern Regions.
Lantheus Holdings Inc - Pylarify is Expected to Be Broadly Available Throughout U.S. by Year End.